Immuno-oncology therapies: a looming mid-life crisis?

Published: 15 March 2022
Commentary
Hansoo Kim,
Danny Liew,
Stephen Goodall

The introduction of immune-oncology therapies for the treatment of cancer marked a shift away from targeting cells to utilising the immune system to fight cancer. These therapies have become standard of care for many different tumour types [1]Watson GA, Doi J, Hansen AR, Spreafico A. Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift? Br. J. Pharmacol. 2020. 86; 17, 3–1768.Watson GA, Doi J, Hansen AR, Spreafico A. Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift? Br. J. Pharmacol. 2020. 86; 17, 3–1768. as they offer the possibility of long-term survival and improved toxicity profile for cancer patients when compared to chemotherapies.

Read now